Drug Trial Radar · NCT07859813
A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of ARO-INHBE in adults with suspected metabolic dysfunction-associated steatohepatitis (MASH).
Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
Interventions
ARO-INHBEDrug
Subcutaneous (SC) injection
PlaceboDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Liver Fat Content (LFC) by Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 48Time frame: Baseline, Week 48
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.